World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
135
Citations
67013
World Ranking
2072
National Ranking
1173

Overview

Mark Lebwohl is affiliated with the Icahn School of Medicine at Mount Sinai in the United States. Their research primarily spans the fields of medicine and immunology and microbiology, with significant contributions to subfields such as immunology, dermatology, pathology and forensic medicine, rheumatology, and economics and econometrics.

Their scholarly work addresses several main topics, including:

  • Psoriasis: Treatment and Pathogenesis
  • Dermatology and Skin Diseases
  • Autoimmune Bullous Skin Diseases
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical studies and practices
  • Asthma and respiratory diseases
  • Nonmelanoma Skin Cancer Studies

Lebwohl has published extensively in various venues, with frequent appearances in:

  • Journal of the American Academy of Dermatology
  • SKIN The Journal of Cutaneous Medicine
  • Dermatology and Therapy
  • British Journal of Dermatology
  • Journal of Drugs in Dermatology

Some recent papers by Lebwohl or involving their collaboration include:

  • "Bimekizumab versus Secukinumab in Plaque Psoriasis," 2021, New England Journal of Medicine
  • "Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies," 2020, Journal of the American Academy of Dermatology
  • "Trial of Spesolimab for Generalized Pustular Psoriasis," 2021, New England Journal of Medicine
  • "Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures," 2020, Journal of the American Academy of Dermatology
  • "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial," 2021, The Lancet

Lebwohl frequently collaborates with a set of co-authors notable for their recurrent contributions, including:

  • Bruce Strober
  • Andrew Blauvelt
  • April W. Armstrong
  • Kim Papp
  • Linda Stein Gold

Best Publications

  • Secukinumab in plaque psoriasis--results of two phase 3 trials.

    Richard G. Langley;Boni E. Elewski;Mark Lebwohl;Kristian Reich

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

    Alan Menter;Alice Gottlieb;Steven R. Feldman;Abby S. Van Voorhees

  • The Impact of Psoriasis on Quality of Life: Results of a 1998 National Psoriasis Foundation Patient-Membership Survey

    Gerald Krueger;John Koo;Mark Lebwohl;Alan Menter

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics

    Alice Gottlieb;Neil J. Korman;Kenneth B. Gordon;Steven R. Feldman

  • A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

    Gerald G. Krueger;Richard G. Langley;Craig Leonardi;Newman Yeilding

  • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

    Alan Menter;Bruce E. Strober;Daniel H. Kaplan;Dario Kivelevitch

  • Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Mark Lebwohl;Bruce Strober;Alan Menter;Kenneth Gordon

  • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Christopher E M Griffiths;Kristian Reich;Mark Lebwohl;Peter van de Kerkhof

  • CTLA4Ig-mediated blockade of T cell costimulation in patients with psoriasis vulgaris

    Judith R. Abrams;Mark G. Lebwohl;Cynthia A. Guzzo;Brian V. Jegasothy

  • Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis. Section 3. Guidelines of Care for the Management and Treatment of Psoriasis With Topical Therapies

    Alan Menter;Neil J. Korman;Craig A. Elmets;Steven R. Feldman

  • A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

    Mark Lebwohl;Stephen K. Tyring;Tiffani K. Hamilton;Darryl Toth

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

    Alan Menter;Neil J. Korman;Craig A. Elmets;Steven R. Feldman

  • Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

    Amy S. Paller;Wynnis L. Tom;Wynnis L. Tom;Mark G. Lebwohl;Robin L. Blumenthal

  • Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    Kenneth B Gordon;Bruce Strober;Mark Lebwohl;Matthias Augustin

  • National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

    Alexa B. Kimball;Dafna Gladman;Joel M. Gelfand;Kenneth Gordon

  • Ingenol mebutate gel for actinic keratosis.

    Mark Lebwohl;Neil Swanson;Lawrence L. Anderson;Anita Melgaard

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

    Alan Menter;Neil J. Korman;Craig A. Elmets;Steven R. Feldman

  • Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

    Mark G. Lebwohl;Hervé Bachelez;Jonathan Barker;Giampiero Girolomoni

  • Methotrexate and psoriasis: consensus conference.

    Robert E. Kalb;Bruce Strober;Gerald Weinstein;Mark Lebwohl

  • In the clinic. Psoriasis.

    Rita V Patel;Mark Lebwohl

Frequent Co-Authors

Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Alan Menter
Alan Menter Texas A&M University
Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Kim Papp
Kim Papp Probity Medical Research
Craig L. Leonardi
Craig L. Leonardi Saint Louis University
Richard G. Langley
Richard G. Langley Dalhousie University
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Emma Guttman-Yassky
Emma Guttman-Yassky Icahn School of Medicine at Mount Sinai
Gerald G. Krueger
Gerald G. Krueger University of Utah
Carle Paul
Carle Paul Federal University of Toulouse Midi-Pyrénées

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Medicine, several online degrees and career pathways offer flexible entry points into the healthcare field. Many aspiring healthcare professionals begin with lpn online programs, which provide a faster route to becoming a Licensed Practical Nurse without sacrificing quality education.

For those looking to advance further, mental health is a growing specialty. Pursuing a fastest post master's pmhnp can help registered nurses specialize as Psychiatric Mental Health Nurse Practitioners in less time through flexible, online formats.

Leadership roles in healthcare are also in demand. Students interested in administration can explore the best online mha programs that blend business, leadership, and healthcare knowledge. Additionally, cost-savvy individuals may want to compare the cheapest online master degree in healthcare administration for affordable ways to boost their credentials.

Each of these online healthcare pathways offers unique advantages, helping you shape a rewarding and versatile medical career based on your interests and professional goals.

Best Scientists Citing Mark Lebwohl

Trending Scientists